INTRODUCTION
The possibility of enzyme replacement therapy for various diseases has attracted wide interest in recent years. Ideas currently being explored included direct injection of the enzyme, enzyme modification by druglike agents to increase or alter pre-existing catalytic activity, enzymes immobilized on insoluble matrices or gels, and enzymes encapsulated in some sort of semipermeable container. (For the proceedings of a recent conference, see reference 1).
Ihler, Glew, and Schnure (2) have shown that enzymes can enter erythrocytes through holes opened during reversible hypotonic hemolysis and become permanently entrapped after addition of isotonic saline. The resulting enzyme-loaded erythrocytes might be useful in two types of clinical situations. First, in diseases involving the accumulation of intracellular substrates in phagocytic cells, the enzyme could be introduced into the phagocytic cell during phagocytosis of the enzymecontaining erythrocyte. Depending on how the erythrocyte was pretreated, it can be directed to a unique organ, notably the spleen or the liver (3) . Enzyme therReceived for publication 17 December 1974 and in revised form 18 April 1975. apy of sphingolipidoses, such as Gaucher's disease, which involve these visceral organs, for example, might thus be feasible. Secondly, it should be possible to degrade circulating small molecules by circulating enzyme-loaded erythrocytes, provided (a) the substrate diffuses or is transported into the erythrocyte sufficiently rapidly, (b) the enzyme is active inside the erythrocyte, and (c) the enzyme-loaded erythrocyte continues to circulate more or less normally. As a model system we have chosen initially to begin with the enzyme uricase and its substrate uric acid, since this system can be easily studied both in vitro and in vivo. This reaction is commonly employed by many living organisms (but not humans) to dispose of uric acid. The products of the reaction are not toxic, and even in humans as much as 25% of the uric acid is metabolized in the intestines by bacteria to allantoin and further degradation products, which are reabsorbed and excreted by the kidney (4) . Since uric acid is a normal end product with no known function in vivo, the possibility of degrading too much of the substrate is not an important consideration. Animals or birds could be used to demonstrate whether uricase-loaded erythrocytes can in fact lower the plasma urate concentration.
In this work, we show that uric acid is transported into hemolysed erythrocytes at the same rate and with the same characteristics as normal erythrocytes. When the hemolyzed erythrocytes are loaded with excess uricase, the uric acid is degraded as fast as it enters the cell. The reaction is shown to be catalyzed by intracellular enzyme and not by enzyme released by lysed cells or enzyme bound to the cell surface. METHODS Materials Pig liver uricase (2 mg/ml) was purchased from Boehringer Mannheim Corp., New York. [2-14C] 7.4 . At this pH, the enzyme has a specific activity of 1.3 U/mg. When assayed under optimal conditions (pH 8.5, borate buffer), the enzyme has a specific activity of 4.5 jumol/mg. The optical assay for activity consisted of following the decrease in absorption at 290 nm in a Gilford recording spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio) (5). The radioisotope assays were generally carried out in a volume of 0.2 ml in a buffer consisting of 0.9%o NaCl; 500 mg/liter glucose; 4 mM KCl; and 0.02 M sodium phosphate buffer, pH 7.4. Loaded erythrocytes, if present, were usually used at hematocrit of 25%.
Uric acid concentrations, unless otherwise noted, were 0.3 mM. Radioactive uric acid was usually present at about 106 cpm/Lmol.
10-pl samples of the reaction mixture were withdrawn and placed in 0.5 ml of ice-cold distilled water (this dilution lyses the erythrocytes if present and reduces the ionic strength of the assay mixture). The sample (0.5 ml) was then passed through a small TEAE column (0.25 ml packed volume) in an eye dropper. The column was washed with an additional 0.5 ml of distilled water and the entire eluate was counted in Triton X-100 counting medium in a Packard scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill. Iug/ml in the hemolysis solution. The cells contained about 1.8 X 106 cpm/ml of erythrocytes at the beginning of the efflux experiment. At various times, 0.1-ml samples were pipetted into 2 ml of buffer and the cells were removed by centrifugation. Samples of the supernate were counted to determine extracellular radioactivity.
Lactate production. Cells were incubated in the same buffer used for the 'Na efflux experiments except that glucose where present was 5.6 mM, hexokinase at 40 ,ug/ ml, adenine at 5 mM, and guanine at 2.5 mM. At zero time and 60 min, samples were precipitated with an equal volume of 8% perchloric acid and the precipitate was removed by centrifugation. The solution was adjusted to pH 7-8 with K2COs, and the precipitate was removed by centrifugation. Samples were assayed for lactate with lactic dehydrogenase and hydrazine buffer (6) .
RESULTS
Rate of transport of uric acid. Uric acid is believed to enter erythrocytes by a passive carrier mechanism (7, 8) . Hemolysis might have little effect on this carrier system, or might instead result in loss or inactivation of the carrier protein, or create pores in the membrane through which uric acid could freely enter or exit. We have compared the rates of entry and exit of uric acid into normal and hemolysed erythrocytes and find them to be very similar ( Fig. 1, top) . In studies on urate entry, the erythrocytes were suspended at a hematocrit of 5-15% in buffer or plasma containing radioactive uric acid. After various intervals the intracellular urate was determined by filtration of the cells on glass fiber filters (similar results are obtained by centrifuging the cells). For exit, cells preequilibrated with urate -were diluted 1/50 into buffer and the rate of exit of the radioactive uric acid was determined.
Since the concentration of uric acid in the intracellular water phase is equal to the extracellular concentration at equilibrium (7), we have used the following equations to describe the entry and exit of uric acid.
Ci -CO where c. is the concentration outside the cell, c4 is the intracellular concentration, and c. is the initial equilibrium intracellular concentration for the exit equation.
The data from Fig. 1 , top, are replotted according to these equations in Fig. 1 , below. Comparison of entry and exit data shows that hemolysed and normal cells have the same rate constants (0.07 min') for both entry and exit, indicating that uric acid is transported similarly by both types of erythrocytes. The rate constant for entry in each case is equal to the rate constant for exit, as would be expected for a system with an equilibrium constant of unity.
Plasma has no effect on the rate of urate transport when compared with buffer (exp. 2, Table I ). Thus plasma does not contain significant concentrations of a competitive inhibitor for uptake.
The rate of entry is temperature dependent. At 260C the rate is about one-half the rate at 370C. The rate of uric acid transport at 00C is extremely slow, less than 1% of the rate at 370C (exps. 3 and 4, Table I ).
Over the range of uric acid concentrations we have examined (up to 1.2 mM), there is no significant change in the rate constant, indicating that the carrier is not saturated in this concentration range (exps. 5 and 6, Table I ). Lassen (7) has shown for normal cells that at uric acid concentrations above 2 mM (almost 10-fold higher than the physiological concentration), the rate constant decreases, implying the existence of a saturable carrier system.
Hypoxanthine is known to inhibit the uptake of uric acid by a competitive process (8) . Entry into both hemolysed and normal erythrocytes is markedly inhibited by 5 mM hypoxanthine (exps. 7 and 8, Table I ). Since this inhibition is probably due to competition for a common carrier, this observation supports the idea that uric acid transport into hemolyzed cells, as in normal cells, is carrier-mediated.
After hemolysis, much of the intracellular contents are lost and as a result it would be expected that the aqueous space of the cell should increase. In agreement The rate constants were determined as discussed in Fig. 1 From the insert in Fig. 2, 9 .6 U/liter erythrocytes would be expected to produce a rate 40% of maximum. The initial relative rate shown in Fig. 2 is 55% of the calculated maximum, which is in reasonable agreement with the expected value.
The kinetics of the reaction catalyzed by enzyme released from sonicated cells is also shown *in Fig. 2, where it is seen that the rate of reaction by free enzyme is approximately the same as that for the encapsulated enzyme. It is concluded, therefore, that the enzyme is not present in great excess within the cell.
Since the enzyme in this experiment is not present in excess in the cell and also is not significantly limiting, 598 it must be approximately the maximum effective concentration. Fig. 3 shows the kinetics of the reaction in cells loaded with 130 U of uricase/liter of erythrocytes. The rate follows closely the kinetics predicted by the entry-limiting model. The presence of excess enzyme is shown by the rate of urate hydrolysis observed with the sonicated erythrocytes, which is approximately sevenfold greater than intact cells. Thus these cells contain about seven times as much enzyme as is actually necessary to achieve maximal rates. These data suggest that only about 20 U/liter of erythrocytes are necessary to achieve maximal rates of urate degradation.
Although we have no direct demonstration that enzyme is contained in 100% of the hemolyzed erythrocytes, the observed rate of degradation closely follows the calculated maximum rate. This calculation assumes that 100% of the cells contain enzyme and suggests that most of the cells do contain enzyme.
Several observations eliminate the possibility that the observed reaction is actually being catalyzed by extracellular enzyme derived from lysed cells or incomplete washing. After the cells were incubated for 25 min, as in the experiment shown in Fig. 2 , the cells were centrifuged and removed, and the incubation was continued with the supernatant fraction. Degradation of uric acid ceases when the cells are removed, indicating that the enzyme was removed with the erythrocytes. When labeled uric acid was added to the supernate after the cells were removed by centrifugation, none of the added uric acid was degraded. We conclude therefore that all the enzyme was intracellular (or at least bound to the cells), that the cells did not lyse during the incubation, and that uric acid hydrolysis occurred within the cell.
To eliminate the remote possibility that the enzyme is adsorbed to the surface of the cell, rather than being intracellular, we have used hypoxanthine to inhibit the rate of uptake of uric acid into the cell. We showed previously that 5 mM hypoxanthine decreases the rate of uric acid transport about sevenfold (Table I) . However, this concentration also inhibits uricase activity about twofold (data not shown). Uricase is not inhibited by 2 mM hypoxanthine (Fig. 4) , but the rate of transport is decreased to only one-half the rate obtained in the absence of hypoxanthine. Fig. 4 shows that 2 mM hypoxanthine decreases the rate of reaction by enzyme-loaded erythrocytes to about one-half the value observed in the absence of hypoxanthine, a value consistent with the decrease in the rate of entry of uric acid. This result indicates that the enzyme is probably not bound to the surface of the cell but rather that the reaction actually proceeds intracellularly, catalyzed by intracellular enzyme. We have not examined in detail the rate of transport of the product across the membrane. However, the rate must be relatively rapid since most of the product remains in the supernate when the cells are removed (Fig. 1 and other data not shown) . The removal of some of the product with the erythrocytes, however, is also consistent with the idea that the reaction proceeds within the cell. Fig. 2 in buffers, demonstrating that the plasma does not contain an inhibitor of uricase (data not shown). We have assayed plasma and erythrocytes (normal and hemolyzed, sonicated and unsonicated) for endogenous uricase activity and found none. Thus, the enzyme activities discussed above are those of added enzyme and do not represent endogenous activity. Ion transport and glycolysis in hemolysed cells. Hemolysed erythrocytes are known to transport sodium and potassium via the ouabain-sensitive, ATP-requiring transport system (10) . Our enzyme-loaded erythrocytes also transport sodium normally. In these experiments, 'Na (with or without variable amounts of nonradioactive sodium) was introduced into the cell at the time of hemolysis. Subsequent exit of the trapped sodium was determined by centrifugation of the cells and determination of the amount of radioisotope in the supernate. Efflux is time-dependent and about 80% of the sodium efflux can be prevented by the addition of ouabain (Table II) .
To lend further support to the idea that enzyme-loaded cells transport sodium, enzyme-loaded cells were fractionated on linear Ficoll sucrose density gradients and the enzyme levels and the sodium transport were determined on the various fractions. Most of the enzyme activity was found in the area of 10% Ficoll and near the top of the 65-40% sucrose gradient. The cells at these densities also transported sodium (data not shown). This, of course, does not prove that the enzyme-containing cells transport sodium, but it is consistent with this idea.
The energy for ion transport by hemolysed cells can be derived either from ATP itself (introduced during hemolysis) or from inosine (10) . If enzyme-loaded cells are to survive in vivo, however, they must be able to use glucose as the energy source and have an intact glycolytic pathway. Schrier (11) has shown that in extensively hemolysed erythrocyte ghosts, the level of all the glycolytic enzymes is extremely low. However, we would expect that if the cells are kept concentrated during hemolysis by the addition, for example, of only 4 vol water to 1 vol cells, a substantial residual level (. 20% of normal) of the glycolytic enzymes should remain in the cells. These cells might retain sufficient capacity for glycolysis despite the lower levels of these enzymes. Even if they do not retain such a capacity, it should be possible to restore enzyme levels by using as the hemolysis medium a dialyzed extract of sonicated or freeze-thawed cells, which should contain the appropriate proportions of each enzyme in the same concentrations as they normally occur in the cell. As an alternative, glycolysis might be enhanced by simply including hexokinase in the hemolysis medium, since hexokinase is the rate-limiting enzyme under ordinary circumstances.
We have examined lactate production by hemolysed cells and their capacity to transport 'Na by using glucose as energy source. The data in Table III shows that ghosts are capable of transporting intracellular sodium at comparable rates, with either inosine or glucose as the energy source. The data in Table IV moved by centrifugation and since hypoxanthine inhibits both the rate of entry and the rate of reaction to the same extent. Uricase-loaded erythrocytes are potentially capable of removing as much uric acid as the human kidney. When loaded with an excess of enzyme, the rate of transport and the rate of degradation of uric acid are both about 21 Amol uric acid/liter per min at a serum urate concentration of 0.3 mM (5 mg/100 ml). At higher or lower serum urate concentrations, the rate would be proportionately higher or lower. The average daily production of uric acid is about 4.4 mmol/day (12, 13) , so that it would require about 150 ml of enzyme-loaded erythrocytes to degrade this amount of uric acid.
It is important to note that enzyme-loaded erythrocytes can be useful only if the rate of enzymatic reaction is sufficiently rapid to achieve the desired effect. This in turn depends largely on the serum substrate concentration and the kinetic constant for transport. It can readily be calculated, from known values for the concentrations and kinetic constants, that some substrates cannot be degraded rapidly enough to obtain a significant lowering of serum concentrations.
Enzyme-loaded erythrocytes are capable of ion transport and glycolysis, both probably necessary for in vivo survival. Ion transport is nearly normal, but the capacity for glycolysis is somewhat reduced. We assume this is due either to a decrease in the levels of intracellular glycolytic enzymes or to depletion of adenine or pyridine nucleotides. If so, it should be relatively easy to restore normal rates of glycolysis by supplementing the erythrocytes with these nucleotides and enzymes. The simplest way to ensure normal concentrations of enzymes would be to use a dialyzed extract of freeze-thawed or sonicated erythrocytes as the hypotonic hemolysis medium. Nucleotides could be added as desired. We are only beginning to explore the question of cell survival, but our preliminary results in birds indicate survival times up to 70% of normal.
If the remaining problems can be solved, erythrocytes loaded with any of several dozen enzymes or proteins could play a useful therapeutic role in a number of different diseases. One such possibility, closely related to uric acid metabolism, would be the use of human erythrocyte hypoxanthine-guanine phosphoribosyl transferase (HGPRT) for human HGPRTase deficiency.
